FDA approves pancreatic cancer drug that extends patients’ lives

In trials, Revolution Medicines’ daraxonrasib nearly doubled average survival times for one of the deadliest cancers.

The Food and Drug Administration has approved a new pancreatic cancer drug, a pill that nearly doubled patients average survival times for one of the deadliest cancers when taken instead of chemother…

წყარო: The Washington Post